Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2021-11-05 Major Shareholding Noti…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is the standard Korean regulatory filing for disclosing significant changes in share ownership (often referred to as the '5% rule' filing). It details the reporter (Kim Deok-sang), special related parties, changes in shareholding ratios, and the purpose of holding (management influence). This corresponds to the 'Major Shareholding Notification' category.
2021-11-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This document details the change in share ownership by an executive (CEO Baik Young Ok) due to a stock repurchase agreement. This falls under the category of 'Director's Dealing' (DIRS), which covers insider transactions and changes in shareholdings by company directors and executives.
2021-11-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Choi Seuk Keun) of Eubiologics. This type of filing, which details personal share transactions by company directors and executives, is classified as 'Director's Dealing' (DIRS).
2021-11-05 Korean
투자판단관련주요경영사항('EuTCV (장티푸스 접합 백신)' 임상 2/3상 시험 종료)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Eubiologics regarding the completion of a Phase 2/3 clinical trial for their typhoid conjugate vaccine (EuTCV). It details the clinical trial results, safety data, and future regulatory plans. This type of disclosure, which reports on significant business developments or material events (clinical trial outcomes), is classified as a general regulatory filing (RNS) in the absence of a more specific category like 'Legal Proceedings' or 'M&A'.
2021-11-01 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) meeting/presentation scheduled for 2021-11-02. It provides details such as the date, location, purpose, and the fact that IR materials will be posted on the Korea Exchange (KIND) system. Since this is an announcement of an event and the availability of materials rather than the presentation itself, it falls under the category of a Report Publication Announcement or general regulatory filing. Given the specific nature of announcing an IR event, 'RPA' is the most accurate classification.
2021-10-29 Korean
투자판단관련주요경영사항('ATGC-100주(보툴리눔 독소 제제)' 임상 3상 시험 종료)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from Eubiologics regarding the completion of a Phase 3 clinical trial for their product 'ATGC-100'. It details the trial results, safety data, and future regulatory plans. Since this is a specific corporate announcement regarding material business developments (clinical trial results) that does not fit into categories like financial reports, dividends, or governance, it falls under the general regulatory filing category.
2021-10-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.